MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas

MediVet Biologics, a leader in Veterinary Regenerative Medicine & Biologic Solutions, announces today that a second US laboratory is to open in Manhattan, Kansas in early October, 2015.

Manhattan, KS (PRWEB) August 26, 2015

MediVet Biologics, a leader in Veterinary Regenerative Medicine & Biologic Solutions, announces today that a second US laboratory is to open in Manhattan, Kansas in early October, 2015. The location of the lab is in accordance with the continued partnership and long-term growth of research and development through collaboration with researchers from Kansas State University's College of Veterinary Medicine.

"The new facility will expand capacity for MediVet Biologic's core product line, including in-house and on-site autologous stem cell processing and training, cryo-storage of cell therapy products, Platelet Rich Plasma (PRP) and Autologous Conditioned Serum (ACS) services for the North America Animal Health community", said MediVet Biologics CEO Jeremy Delk. Recently, MediVet Biologics licensed the Intellectual Property rights to produce an Allogeneic Stem Cell Therapy product, MB-007, from the Kansas State University Research Foundation for potential orthopedic and internal medicine applications for both veterinary and human clinical use. The new facility will be the site of commercial development of MB-007 and support clinical testing by providing proximity to collaborators at Kansas State University.

According to Mark Weiss, Ph.D., Inventor of MB-007 and Professor at Kansas State University's College of Veterinary Medicine, "We offer training in Stem Cells and Regenerative Medicine at the University through a graduate certificate program. It is our job as educators to prepare our students in evidence-based medicine, and, in the Animal Health field, that includes regenerative medicine and advanced biologics. We are excited about the new MediVet Biologics laboratory being located in Kansas State University's Innovation Park, since this will facilitate collaboration between academia and MediVet Biologics, a successful innovator in animal health."

The facility will enable expansion into the equine marketplace through collaboration with Dr. Jim Lillich, DVM, MS, DACVS. The facility will also provide a second site for production of K9-ACV, an autologous therapeutic canine cancer vaccine and support clinical testing by Kansas State University veterinary oncologist, Dr. Raelene Wouda in a joint effort with John R. Yannelli Ph.D. from the University of Kentucky College of Medicine.

"Our company has grown by providing Veterinarians affordable, progressive treatment options for their patients. We envision this second laboratory facility as a place of education and collaboration and look forward to including the local and regional Veterinary community in the continued development of our animal health product line", said MediVet Biologics CEO Jeremy Delk.

About MediVet Biologics:

MediVet Biologics is a global leader in veterinary regenerative medicine and biological solutions. With corporate offices in Central, Kentucky, and Sydney, Australia the company provides the global animal health community with progressive and affordable treatment options for canine, feline and equine patients. MediVet Biologics' accomplishments in the regenerative medicine market have given way to an incredible pipeline of technological advancements and the ability to successfully bring those animal health products to Veterinary community. MediVet Biologics continues to bring together leading researchers in the animal health and human medical field to advance Veterinary medicine for animals needlessly suffering in pain.
To learn more about MediVet Biologics, call 1.800.365.9168 or visit us at

For Company or Product Inquiries contact:

Thomas Masterson
(859) 885-7111 EXT 303

For the original version on PRWeb visit:


Read more:

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…